Key Finding
This protocol describes a planned randomized controlled trial to evaluate infrared moxibustion's effects on blood lipid levels, gut microbiota, and brain structure in 158 patients with mild hyperlipidemia, with results pending.
Researchers are studying whether infrared moxibustion, a modern heat therapy based on traditional Chinese medicine, can help people with mildly elevated cholesterol levels. High cholesterol is a major risk factor for heart disease and cognitive decline, so finding effective early treatments is important. This study will enroll 158 patients with mild hyperlipidemia (high cholesterol) and randomly divide them into two groups. One group will receive genuine infrared moxibustion treatment, while the other receives a sham (placebo) treatment. Sessions will occur twice weekly for eight weeks. Researchers will measure cholesterol levels, cognitive function, depression, anxiety, and sleep quality at the beginning of the study and at 4, 8, and 12 weeks. They'll also examine changes in gut bacteria, a metabolite called TMAO (which affects heart health), and brain structure using imaging. This comprehensive approach aims to understand not just whether infrared moxibustion works for lowering cholesterol, but also how it might work through effects on the gut-brain connection. The study is particularly interesting because it looks at multiple health factors beyond just cholesterol numbers, including mental health and sleep quality. Since this is a protocol paper describing a planned study, results aren't yet available, but the research design appears robust with its randomized, placebo-controlled approach. If you're interested in moxibustion or acupuncture-related therapies for cholesterol management, consult with a licensed acupuncturist or qualified traditional Chinese medicine practitioner.
This randomized controlled trial protocol outlines a study evaluating infrared moxibustion for mild hyperlipidemia in 158 patients. Participants will be randomized to genuine or sham infrared moxibustion groups, receiving treatments twice weekly for 8 weeks. Primary outcomes include blood lipid profiles measured at baseline, 4, 8, and 12 weeks post-treatment. Secondary outcomes encompass Montreal Cognitive Assessment scores, Hamilton Depression and Anxiety Rating Scale scores, and Pittsburgh Sleep Quality Index scores at the same intervals. Notably, the study incorporates mechanistic investigations through gut microbiota analysis, measurement of the cardiovascular risk marker TMAO (trimethylamine N-oxide), and MRI assessment of brain gray matter volume changes at baseline and 8 weeks. This multimodal approach addresses a significant gap in evidence-based research on infrared moxibustion, potentially elucidating mechanisms involving the gut-brain-cardiovascular axis. As a protocol publication, efficacy data are pending, but the rigorous methodology and comprehensive outcome measures position this trial to provide valuable clinical evidence.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Dysregulation of m7G RNA modifications, catalyzed by three major methyltransferase complexes in the CNS, is associated with the pathogenesis of multiple neurological diseases including Alzheimer's disease, ALS, epilepsy, glioblastoma, and ischemic stroke.
📌 Acupuncture significantly reduced thyroid antibodies (TPOAb and TGAb) and TSH levels in Hashimoto thyroiditis patients, though methodological limitations prevent reliable clinical recommendations pending higher-quality research.
📌 Liproxstatin-1 significantly reduced cerebral ischemia-reperfusion injury in rats by inhibiting ferroptosis through increasing neuroprotective factors GPX4 and FTH1 while decreasing ferroptosis markers NOX1, ACSL4, COX2, and TFR1.